Is Moderna Stock Outperforming the Dow?

Company Overview - Moderna, Inc. has a market cap of $19.7 billion and specializes in messenger RNA (mRNA) medicines, with operations in the United States, Europe, and global markets [1] - The company has a diverse vaccine portfolio that includes vaccines for respiratory diseases, latent and enteric viruses, public health threats, and bacterial diseases [1][2] - In addition to vaccines, Moderna develops oncology therapeutics and treatments for rare diseases such as cystic fibrosis and metabolic disorders [2] Stock Performance - Shares of Moderna have decreased by 9.7% from their 52-week high of $55.20, but have increased by 97.9% over the past three months, outperforming the Dow Jones Industrials Average, which rose by 1.3% in the same period [3] - Year-to-date, MRNA stock is up 69%, significantly exceeding the Dow Jones' marginal gain, and has surged 64.6% over the past 52 weeks compared to the Dow Jones' 12.3% return [3] Financial Results - In Q4 2025, Moderna reported revenue of $678 million, surpassing expectations, and a narrower net loss of $826 million compared to a $1.1 billion loss a year earlier [5] - The company reiterated its 2026 outlook of up to 10% revenue growth and reported a 31% year-over-year reduction in R&D spending in Q4 [5] Pipeline Developments - The stock rally was supported by progress in the pipeline, including full enrollment in a Phase 3 norovirus vaccine trial with data expected in 2026 and full enrollment in the Phase 2 intismeran autogene bladder cancer trial [6] - Compared to its rival Eli Lilly and Company, which has seen a YTD decline of 6.2% and an 8.4% gain over the past year, Moderna's stock performance has been notably stronger [6]